Hindustan Coca-Cola Beverages Names New CEO
BANGALORE, India, July 15, 2025 /PRNewswire/ -- The Coca-Cola Company announced today that…
Fat Burner For Men Launched Over the Counter in USA PhenQ Medically Accredited Thermogenic Fat Burning Supplement for Men
Glasgow, UK, July 13, 2025 (GLOBE NEWSWIRE) -- Introduction: Why PhenQ Is…
Beach Cities Commercial Bank Announces Leadership Changes
IRVINE, Calif.--(BUSINESS WIRE)--Beach Cities Commercial Bank (OTCQB:BCCB) announced that President Jeffrey Redeker…
FIS and Virtus sign landmark Memorandum of Understanding to advance inclusion in winter sports
Jul 02, 2025 - The International Ski and Snowboard Federation (FIS) and…
Bain & Company appoints Shintaro Okuno as new Regional Managing Partner for Asia-Pacific
SINGAPORE, July 2, 2025 /PRNewswire/ -- Bain & Company has appointed Shintaro…
The Ensign Group, Inc. Announces Retirement of Its Executive Chairman
June 20, 2025 16:30 ET | Source: The Ensign Group, Inc. SAN…
Flexsys Announces Price Increase for Insoluble Sulfur in India
AKRON, Ohio, June 18, 2025 /PRNewswire/ -- Flexsys has announced that it…
Shutterstock Unveils Bold New Brand Identity as the Universal Ingredient to Help Business Leaders Fuel Great Work
Shutterstock is redefining its impact in the business of creativity with a…
Infomerics Appoints Shubham Jain as Group CEO of Infomerics Ratings
NEW DELHI, June 16, 2025 /PRNewswire/ -- Infomerics Valuation and Rating Ltd,…
![[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients](https://i1.wp.com/ml-eu.globenewswire.com/media/NTJlMDkyZjktNGMwNi00N2YyLTkyZmQtZTIwMWJlNzgxOWYyLTEwMTI2MjEtMjAyNS0wNi0xNS1lbg==/tiny/F-Hoffmann-La-Roche-Ltd.png?w=420&resize=420,280&ssl=1 "[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients")
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…